BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36393999)

  • 1. The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series.
    Liu J; Hsia CC
    Adv Hematol; 2022; 2022():8119270. PubMed ID: 36393999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
    Gonzalez-Lopez TJ; Bermejo N; Cardesa-Cabrera R; Martínez V; Aguilar-Monserrate G; Pérez Segura G; García AD; Luis-Navarro J; Lakhwani S; Acedo N; Lozano ML; Bernat S; Torres-Tienza A; Ruano A; Jarque I; Galán Alvarez P; Benet Campos C; Marcellini-Antonio S; Jimenez-Bárcenas R; Martínez-Carballeira D; de Miguel Llorente D; Perona Blázquez Á; González-Gascón-Y-Marín I; Lopez-Ansoar E; Alonso Alonso JM; Bengochea-Casado ML; Díaz Gálvez FJ; Moretó A; Moreno G; Hernández-Martin R; de Cabo E; Davila-Valls J; Cuesta A; Pastoriza Cruz C; Hermida G; García C; Pozas-Mañas MA; Aguilar-Franco C; Fernandez-Jimenez D; Navas-Elorza B; López-Santamaría Castro C; Lorenzo Vizcaya A; Ortín X; Pintos MG; Piernas S; Díaz-Santa J; Soto-Ortega I; Provan D; García-Donas Gabaldón G
    Blood; 2024 Jun; ():. PubMed ID: 38843478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
    Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
    Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
    Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
    Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib.
    Cooper N; Altomare I; Thomas MR; Nicolson PLR; Watson SP; Markovtsov V; Todd LK; Masuda E; Bussel JB
    Ther Adv Hematol; 2021; 12():20406207211010875. PubMed ID: 33995988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
    Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME;
    Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials.
    Tungjitviboonkun S; Bumrungratanayos N; Jitwimungsanon J; Kheamakulvanich T; Siramongkholkarn S
    Ann Hematol; 2024 Jun; ():. PubMed ID: 38856778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
    McKeage K; Lyseng-Williamson KA
    Drugs Ther Perspect; 2018; 34(10):451-456. PubMed ID: 30459507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained response off therapy after fostamatinib: A chronic refractory ITP case report.
    Auteri G; Biondo M; Mazzoni C; Venturi M; Romagnoli AD; Paglia S; Cavo M; Vianelli N; Palandri F
    Heliyon; 2023 Feb; 9(2):e13462. PubMed ID: 36846652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
    Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y;
    Br J Haematol; 2023 Mar; 200(6):802-811. PubMed ID: 36470677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia.
    Newland A; McDonald V
    Immunotherapy; 2020 Dec; 12(18):1325-1340. PubMed ID: 33023353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series.
    Hughes DM; Toste C; Nelson C; Escalon J; Blevins F; Shah B
    J Adv Pract Oncol; 2021 Jul; 12(5):508-517. PubMed ID: 34430061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
    Paik J
    Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
    Mehta AR; Kefela A; Toste C; Sweet D
    Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fostamatinib for persistent/chronic adult immune thrombocytopenia.
    Newland A; Lee EJ; McDonald V; Bussel JB
    Immunotherapy; 2018 Jan; 10(1):9-25. PubMed ID: 28967793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion.
    Lucchesi A; Fattizzo B; De Stefano V; Ruggeri M; Siragusa S; Vianelli N; Zaja F; Rodeghiero F
    Ther Adv Hematol; 2023; 14():20406207221147777. PubMed ID: 37426835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
    Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB;
    Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
    Dierickx D; Neefs J
    Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).
    Lee EJ; Izak M; Bussel JB
    Br J Haematol; 2020 Apr; 189(2):379-382. PubMed ID: 31900937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fostamatinib for the treatment of immune thrombocytopenia in adults.
    Moore DC; Gebru T; Muslimani A
    Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.